<p><em>Lead program 是一个准备进入第一阶段的 EBV 疫苗候选者，具有预防传染性单核细胞增多症及与 EBV 感染相关的严重长期疾病的潜力</em></p>
<p>, /PRNewswire/ -- Vaccine Company, Inc.（Vaccine Company），一家私人持有的临床前生物技术公司，正在开发针对传染病的下一代疫苗，今天宣布已达成最终协议，将被礼来收购。</p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2987379/Vaccine_Company_Logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="400" height="101" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2987379/Vaccine_Company_Logo.jpg"/></p>
<p>Vaccine Company 的专有体内纳米颗粒（IVN）技术旨在实现抗原展示，以引发与类病毒颗粒疫苗相关的持久免疫反应，同时避免传统 VLP 生产的制造负担。该公司正在推进一个涵盖多种病毒病原体的广泛临床前管线；其主导项目将该技术应用于 Epstein-Barr 病毒（EBV），并拥有一个五抗原的第一阶段准备候选者。考虑到越来越多的证据将 EBV 与多发性硬化症和几种恶性肿瘤联系在一起，预防性疫苗不仅可以预防急性传染性单核细胞增多症，还可以防止感染后可能出现的长期神经和肿瘤后果。</p>
<p>根据协议条款，礼来将收购 Vaccine Company，Vaccine Company 的股东可能会获得高达 15.5 亿美元的现金，包括一次性付款和在达到特定临床和商业里程碑后支付的后续款项。</p>
<p>&#34;我们的项目管线，加上我们专有的体内纳米颗粒（IVN）技术，具有全球影响的潜力，&#34; Vaccine Company 首席执行官 Susan Silbermann，MBA，MA 说，&#34;与礼来合作，我们将能够推进我们的科学，推动项目开发，并最终向全球人民提供疫苗。&#34;</p>
<p>&#34;Epstein-Barr 病毒是世界上最普遍的人类病毒之一，但我们尚未拥有针对它的疫苗。Vaccine Company 建立了一个我们相信可能改变这一现状的平台，&#34; 礼来首席科学官兼产品官、礼来研究实验室总裁 Daniel M. Skovronsky，M.D.，Ph.D. 说。&#34;预防的理由远不止于传染性单核细胞增多症本身——现在的证据将 EBV 与多发性硬化症和几种恶性肿瘤联系在一起，提前打断这一链条可能会显著减少这些疾病的长期负担。&#34;</p>
<p>该交易需满足惯常的成交条件，包括根据 1976 年 Hart-Scott-Rodino 反垄断改进法案的等待期到期。</p>
<p>Lazard 担任独家财务顾问，Cooley LLP 担任 Vaccine Company 的法律顾问。</p>
<p><strong>关于 Vaccine Company</strong></p>
<p>Vaccine Company 是一家私人持有的临床前生物技术公司，成立的目的是将下一代抗原工程引入疫苗科学。该公司的专有体内纳米颗粒（IVN）技术旨在结合 mRNA 和类病毒颗粒方法的优势，以实现对具有挑战性的病毒靶标的持久、多价免疫反应。Vaccine Company 正在推进一系列临床前和 IND 启动项目，主导项目是针对由 Epstein-Barr 病毒引起的传染性单核细胞增多症的预防疫苗候选者。该公司于 2022 年由 ARCH Venture Partners 创立，Luma Group 作为共同创始投资者加入，此外还获得了 Pfizer Ventures、Wellcome Trust、Lilly Ventures 和全球健康投资公司的进一步支持。</p>
<p><strong>联系信息</strong></p>
<p>Morgan Warners, FGS Global</p>
<p>Morgan.warners@fgsglobal.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://edge.prnewswire.com/c/img/favicon.png/query-c2Q9MjAyNi0wNS0yNiZzbj1EQzY3NDA1?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="16" height="16" original-src="https://imageproxy.pbkrs.com/https://edge.prnewswire.com/c/img/favicon.png/query-c2Q9MjAyNi0wNS0yNiZzbj1EQzY3NDA1"/></p>
<p>查看原始内容以下载多媒体：https://www.prnewswire.com/news-releases/vaccine-company-to-be-acquired-by-lilly-to-advance-best-in-class-vaccine-candidates-for-epstein-barr-virus-and-other-infectious-diseases-302781387.html</p>
<p>来源 Vaccine Company</p>

礼来

动态生物技术与基因组 ETF - Invesco

纽交所高增长板生物技术指数 ETF - First Trust

<p>Vaccine Company, Inc. 已与礼来达成最终协议，将以高达 15.5 亿美元的价格被收购。此次收购旨在推进一款针对埃比斯坦 - 巴尔病毒（EBV）的 1 期准备疫苗候选者，该疫苗有望预防传染性单核细胞增多症及相关的长期健康问题。该交易需满足惯常的成交条件，两家公司均认为此次合作将增强疫苗开发和全球健康影响</p>

<p><em>Lead program is a Phase 1-ready EBV vaccine candidate with potential to prevent infectious mononucleosis and the serious long-term conditions associated with EBV infection</em></p>
<div class="lb-trans"><p><em>Lead program 是一个准备进入第一阶段的 EBV 疫苗候选者，具有预防传染性单核细胞增多症及与 EBV 感染相关的严重长期疾病的潜力</em></p>
</div><p>, /PRNewswire/ -- Vaccine Company, Inc. (Vaccine Company), a privately held pre-clinical-stage biotechnology company developing next-generation vaccines for infectious diseases, today announced entry into a definitive agreement to be acquired by Lilly.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- Vaccine Company, Inc.（Vaccine Company），一家私人持有的临床前生物技术公司，正在开发针对传染病的下一代疫苗，今天宣布已达成最终协议，将被礼来收购。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2987379/Vaccine_Company_Logo.jpg" alt="" original-src="https://mma.prnewswire.com/media/2987379/Vaccine_Company_Logo.jpg"/></p>
<p>Vaccine Company's proprietary In Vivo Nanoparticle (IVN) technologies are designed to enable the antigen display known to elicit durable immune responses associated with virus-like particle vaccines, while avoiding the manufacturing burden of traditional VLP production. The company is advancing a broad preclinical pipeline spanning multiple viral pathogens; the lead program applies this technology to Epstein-Barr Virus (EBV) with a five-antigen Phase 1-ready candidate. Given the growing evidence linking EBV to multiple sclerosis and several malignancies, a prophylactic vaccine could prevent not only acute infectious mononucleosis but also the long-term neurological and oncological consequences that may follow infection.</p>
<div class="lb-trans"><p>Vaccine Company 的专有体内纳米颗粒（IVN）技术旨在实现抗原展示，以引发与类病毒颗粒疫苗相关的持久免疫反应，同时避免传统 VLP 生产的制造负担。该公司正在推进一个涵盖多种病毒病原体的广泛临床前管线；其主导项目将该技术应用于 Epstein-Barr 病毒（EBV），并拥有一个五抗原的第一阶段准备候选者。考虑到越来越多的证据将 EBV 与多发性硬化症和几种恶性肿瘤联系在一起，预防性疫苗不仅可以预防急性传染性单核细胞增多症，还可以防止感染后可能出现的长期神经和肿瘤后果。</p>
</div><p>Under the terms of the agreement, Lilly will acquire Vaccine Company, and Vaccine Company equity holders could receive up to $1.55 billion in cash, inclusive of an upfront payment and subsequent payments payable upon the achievement of specified clinical and commercial milestones.</p>
<div class="lb-trans"><p>根据协议条款，礼来将收购 Vaccine Company，Vaccine Company 的股东可能会获得高达 15.5 亿美元的现金，包括一次性付款和在达到特定临床和商业里程碑后支付的后续款项。</p>
</div><p>&#34;Our pipeline of programs, coupled with our proprietary In Vivo Nanoparticle (IVN) technologies, have the potential for global impact,&#34; said Susan Silbermann, MBA, MA, Chief Executive Officer of Vaccine Company, &#34;Together with Lilly, we will be positioned to advance our science, move programs through development, and ultimately deliver vaccines to people around the world.&#34;</p>
<div class="lb-trans"><p>&#34;我们的项目管线，加上我们专有的体内纳米颗粒（IVN）技术，具有全球影响的潜力，&#34; Vaccine Company 首席执行官 Susan Silbermann，MBA，MA 说，&#34;与礼来合作，我们将能够推进我们的科学，推动项目开发，并最终向全球人民提供疫苗。&#34;</p>
</div><p>&#34;Epstein-Barr virus is among the most prevalent human viruses in the world, yet we do not yet have a vaccine against it. Vaccine Company has built a platform we believe may be capable of changing that,&#34; said Daniel M. Skovronsky, M.D., Ph.D., Lilly's chief scientific and product officer, and president, Lilly Research Laboratories. &#34;The case for prevention extends well beyond infectious mononucleosis itself — evidence now links EBV to multiple sclerosis and several malignancies and interrupting that chain earlier could meaningfully reduce the long-term burden of these diseases.&#34;</p>
<div class="lb-trans"><p>&#34;Epstein-Barr 病毒是世界上最普遍的人类病毒之一，但我们尚未拥有针对它的疫苗。Vaccine Company 建立了一个我们相信可能改变这一现状的平台，&#34; 礼来首席科学官兼产品官、礼来研究实验室总裁 Daniel M. Skovronsky，M.D.，Ph.D. 说。&#34;预防的理由远不止于传染性单核细胞增多症本身——现在的证据将 EBV 与多发性硬化症和几种恶性肿瘤联系在一起，提前打断这一链条可能会显著减少这些疾病的长期负担。&#34;</p>
</div><p>The transaction is subject to customary closing conditions, including expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.</p>
<div class="lb-trans"><p>该交易需满足惯常的成交条件，包括根据 1976 年 Hart-Scott-Rodino 反垄断改进法案的等待期到期。</p>
</div><p>Lazard is acting as exclusive financial advisor, and Cooley LLP is acting as legal counsel to Vaccine Company.</p>
<div class="lb-trans"><p>Lazard 担任独家财务顾问，Cooley LLP 担任 Vaccine Company 的法律顾问。</p>
</div><p><strong>About Vaccine Company</strong></p>
<div class="lb-trans"><p><strong>关于 Vaccine Company</strong></p>
</div><p>Vaccine Company is a privately held pre-clinical-stage biotechnology company founded to bring next-generation antigen engineering to vaccine science. The company's proprietary In Vivo Nanoparticle (IVN) technologies are designed to combine the strengths of mRNA and virus-like particle approaches to enable durable, multivalent immune responses to challenging viral targets. Vaccine Company is advancing a pipeline of preclinical and IND-enabling programs, led by a vaccine candidate for the prevention of infectious mononucleosis caused by Epstein-Barr virus. The company was founded in 2022 by ARCH Venture Partners. Luma Group joined as co-founding investor, with further backing from Pfizer Ventures, Wellcome Trust, Lilly Ventures, and Global Health Investment Corporation.</p>
<div class="lb-trans"><p>Vaccine Company 是一家私人持有的临床前生物技术公司，成立的目的是将下一代抗原工程引入疫苗科学。该公司的专有体内纳米颗粒（IVN）技术旨在结合 mRNA 和类病毒颗粒方法的优势，以实现对具有挑战性的病毒靶标的持久、多价免疫反应。Vaccine Company 正在推进一系列临床前和 IND 启动项目，主导项目是针对由 Epstein-Barr 病毒引起的传染性单核细胞增多症的预防疫苗候选者。该公司于 2022 年由 ARCH Venture Partners 创立，Luma Group 作为共同创始投资者加入，此外还获得了 Pfizer Ventures、Wellcome Trust、Lilly Ventures 和全球健康投资公司的进一步支持。</p>
</div><p><strong>Contact Information</strong></p>
<div class="lb-trans"><p><strong>联系信息</strong></p>
</div><p>Morgan Warners, FGS Global</p>
<div class="lb-trans"><p>Morgan Warners, FGS Global</p>
</div><p>Morgan.warners@fgsglobal.com</p>
<div class="lb-trans"><p>Morgan.warners@fgsglobal.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://edge.prnewswire.com/c/img/favicon.png/query-c2Q9MjAyNi0wNS0yNiZzbj1EQzY3NDA1" alt="" original-src="https://edge.prnewswire.com/c/img/favicon.png?sn=DC67405&amp;sd=2026-05-26"/></p>
<p>View original content to download multimedia:https://www.prnewswire.com/news-releases/vaccine-company-to-be-acquired-by-lilly-to-advance-best-in-class-vaccine-candidates-for-epstein-barr-virus-and-other-infectious-diseases-302781387.html</p>
<div class="lb-trans"><p>查看原始内容以下载多媒体：https://www.prnewswire.com/news-releases/vaccine-company-to-be-acquired-by-lilly-to-advance-best-in-class-vaccine-candidates-for-epstein-barr-virus-and-other-infectious-diseases-302781387.html</p>
</div><p>SOURCE Vaccine Company</p>
<div class="lb-trans"><p>来源 Vaccine Company</p>
</div>

Vaccine Company to be acquired by Lilly to advance best-in-class vaccine candidates for Epstein-Barr Virus and other infectious diseases

Fidelity

纳斯达克生物科技指数 ETF - iShares Nasdaq

基因改革 ETF - ARK

医药突破 ETF - ALPS

2 倍做多纳斯达克生物技术 ETF - ProShares

医疗业 ETF - Vanguard

美国制药 ETF - iShares

2 倍做多 LLY ETF - Defiance

生物科技 ETF - VanEck Vectors

2 倍做多 LLY ETF - Direxion

标普生物技术 ETF - SPDR

标普生物技术 3 倍做多 - Direxion

Invesco Nasdaq Biotechnology ETF

医疗业 ETF - SPDR

Lazard

辉瑞

疫苗公司将被礼来收购，以推进针对 Epstein-Barr 病毒及其他传染病的顶级疫苗候选产品